Ifo-Cell (Ifosfamide)

Ifosfamide is a DNA‑cross‑linking alkylating agent. After metabolic activation in the liver, it forms covalent bonds with DNA bases, creating inter‑ and intra‑strand cross‑links that block DNA replication and transcription, ultimately leading to apoptosis of rapidly dividing cancer cells.

The prescribed dose of Ifo-Cell is individualized by the treating oncologist. Factors such as the specific cancer type, disease stage, patient body surface area, renal function, and prior therapies are considered to calculate the appropriate intravenous infusion regimen.

Ifosfamide is classified as Pregnancy Category D, indicating evidence of fetal risk. It is contraindicated in pregnant women and should be avoided during breastfeeding because the drug can be excreted in milk and may harm the infant. Effective contraception is required for women of childbearing potential.

To order Ifo-Cell, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

The primary alternative to ifosfamide within the alkylating class is cyclophosphamide. Both agents share a similar DNA‑cross‑linking mechanism, but ifosfamide generally requires co‑administration of mesna to prevent hemorrhagic cystitis, whereas cyclophosphamide has a different toxicity profile and is often given orally or intravenously.

Ifo-Cell must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration.

Ifo-Cell is given as an intravenous infusion, typically over a period of 1–3 hours depending on the protocol. It is prepared under aseptic conditions, diluted with compatible IV fluid, and administered together with mesna to reduce bladder toxicity. Infusion rates and pre‑hydration are adjusted per patient tolerance.

Serious adverse events include nephrotoxicity, neurotoxicity (such as encephalopathy), severe myelosuppression leading to infection or bleeding, hemorrhagic cystitis, and the potential development of secondary malignancies like therapy‑related leukemia. Prompt monitoring of renal function, neurological status and blood counts is essential.

Ifo-Cell is contraindicated in pregnant women, patients with severe renal impairment, and individuals with known hypersensitivity to ifosfamide or its excipients. Caution is also advised for patients with pre‑existing neurological disorders or uncontrolled infections, as the drug may exacerbate these conditions.